Related Experiment Video

Updated: May 28, 2026

Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model
10:18

Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model

Published on: June 29, 2014

Ryanodine receptor type 2 is required for the development of pressure overload-induced cardiac hypertrophy

Yunzeng Zou1, Yanyan Liang, Hui Gong

  • 1Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, 180 Feng Lin Rd, Shanghai 200032, China. zou.yunzeng@zs-hospital.sh.cn

Hypertension (Dallas, Tex. : 1979)
|October 12, 2011
PubMed

Insights

Ryanodine receptor type 2 (RyR-2) plays a key role in cardiac hypertrophy and adaptation to pressure overload. Reduced RyR-2 impairs calcium release, leading to less compensated hypertrophy and altered signaling pathways.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Physiology

Background:

  • Ryanodine receptor type 2 (RyR-2) is crucial for calcium release in the heart.
  • Its specific role in cardiac hypertrophy development remains unclear.

Purpose of the Study:

  • To investigate the function of RyR-2 in cardiac hypertrophy and adaptation to pressure overload.
  • To elucidate the molecular mechanisms involving RyR-2 during cardiac stress.

Main Methods:

  • Analysis of mice with reduced RyR-2 gene expression (RyR-2(+/-)) and wild-type littermates.
  • Induction of cardiac pressure overload via transverse aortic constriction.
  • Assessment of cardiomyocyte function, cardiac morphology, fibrosis, apoptosis, autophagy, and signaling pathway activation.

Main Results:

  • RyR-2(+/-) cardiomyocytes showed impaired calcium handling and reduced contractility under pressure overload.
  • RyR-2(+/-) mice exhibited less cardiac hypertrophy, fibrosis, and preserved contractility compared to wild-type.
  • Pressure overload-induced activation of calcineurin, ERK, and Akt pathways was abolished in RyR-2(+/-) mice.

Conclusions:

  • RyR-2 is essential for cardiac adaptation to pressure overload.
  • It regulates sarcoplasmic reticulum calcium release, cardiomyocyte survival, and key signaling pathways (calcineurin, ERK, Akt).
  • Targeting RyR-2 may offer therapeutic strategies for cardiac hypertrophy.

More Related Videos

Transverse Aortic Constriction in Mice08:25

Transverse Aortic Constriction in Mice

Published on: April 21, 2010

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cellular Adaptation II: Hypertrophy01:26

Cellular Adaptation II: Hypertrophy

Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...